Results 181 to 190 of about 52,123 (292)

The Role of Sex in Ocular Biometry: A Large-Scale Study of Cataract Candidates in Greece. [PDF]

Ophthalmol Ther
Sakka D, Zisimopoulos A, Kalogera E, Athanasopoulos E, Diamantopoulou K, Halkiadakis I, Konstantopoulou K, Kourentis C, Markopoulos I, Michail I, Paroikakis E, Peponis V, Karampelas M.   +12 more
europepmc   +1 more source

First‐in‐human, phase I, randomized, safety, pharmacokinetic, food‐effect and pharmacodynamic study of a tyrosine kinase 2/Janus kinase 1 inhibitor, SDC‐1801

British Journal of Clinical Pharmacology, EarlyView.
Aim The purpose of this study is to evaluate safety, tolerability, pharmacokinetics (PK), food‐effect (FE) and pharmacodynamics (PD) of an oral tyrosine kinase‐2 (TYK2)/Janus kinase‐1 (JAK1) inhibitor, SDC‐1801, in healthy adult participants. Methods This first‐in‐human study randomized 95 male and female participants.
Chris Brearley, Sam Francis, John Reader, Judi Proctor   +3 more
wiley   +1 more source

Pharmacokinetics and safety of tezepelumab in children with mild, moderate or severe asthma and adolescents with mild‐to‐moderate asthma

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Tezepelumab is a human monoclonal antibody that blocks the activity of thymic stromal lymphopoietin and is approved for adolescents and adults with severe asthma. This analysis assessed pharmacokinetics (PK), pharmacodynamics and safety of tezepelumab up to 85 days postdose in adolescents and children.
Anna Lundahl, Jonathan Grigg, Lubna Abuqayyas, Piotr Kuna, Gillian Hunter, Beata Pawlikowska, Jacob Leander, Michael Levin, Atul Gupta, James Paton, Katharine C. Pike, Jane R. Parnes, Gun Almqvist, Stephanie L. Roseti, on behalf of the study investigators   +14 more
wiley   +1 more source

Lateral similarity and symmetry of biometric data from the LenStar in a population with cataract. [PDF]

PLoS One
Langenbucher A, Wendelstein J, Cayless A, Wagenpfeil S, Hoffmann P, Cooke D, Szentmáry N.   +6 more
europepmc   +1 more source

The effect of mild and moderate hepatic impairment on the pharmacokinetics, safety and tolerability of balcinrenone

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Balcinrenone (previously AZD9977) is a novel selective non‐steroidal mineralocorticoid receptor antagonist (MRA) with a differential mechanism of action relative to approved MRAs. The aim of this trial was to assess the pharmacokinetics, safety and tolerability of balcinrenone in participants with mild and moderate hepatic impairment ...
Anna L. Eriksson, Deeyen Karsanji, Bonifride Tuyishimire, Joanna Parkinson, Maria Heijer, Tadeusz Pawlik, Judith Hartleib‐Geschwindner, Maria Leonsson‐Zachrisson, Hans Ericsson   +8 more
wiley   +1 more source

A multicentre benchmark dataset for comprehensive landmark-based fetal ultrasound biometry. [PDF]

Sci Rep
Di Vece C, Mao Z, Avisdris N, Dromey B, Napolitano R, Ben Bashat D, Vasconcelos F, Stoyanov D, Joskowicz L, Bano S.   +9 more
europepmc   +1 more source

Systemic menopausal hormone therapy treatment patterns in Danish women—A nationwide drug utilization study

British Journal of Clinical Pharmacology, EarlyView.
Abstract Objectives This paper aims to describe the treatment patterns of contemporary systemic menopausal hormone therapy (MHT) in Denmark. Study design This study is a nationwide drug utilization study including an open cohort of all Danish women aged >40 years between 2000–2024.
Hannah K. Wood‐Kurland, Kathrine Kold Sørensen, Amalie Lykkemark Møller, Lina Steinrud Mørch, Mikkel Porsborg Andersen, Thomas Alexander Gerds, Amani Meaidi, Christian Torp‐Pedersen   +7 more
wiley   +1 more source

Comparison of Swept-Source Optical Biometry and Contact A-Scan Ultrasonography for Axial Length Measurement in Eyes with Mature Cataract. [PDF]

Beyoglu Eye J
Ceylan A, Simsek E, Akbas YB, Aydin FO, Yildiz BK.   +4 more
europepmc   +1 more source

Adaptive imatinib regimens can mitigate cumulative toxicity while sustaining hemodynamic benefit: A model‐based simulation of the positioning imatinib for pulmonary arterial hypertension trial

British Journal of Clinical Pharmacology, EarlyView.
ABSTRACT Aims Imatinib improves hemodynamics in pulmonary arterial hypertension (PAH), but dose‐dependent toxicity has limited its clinical development. We aimed to quantify the dose–efficacy–toxicity relationship and evaluate alternative dosing strategies using data from the PIPAH trial.
Medhat M. Said, Robert B. de Mooij, Dian Jiao, Reitze J. Ovelgonne, Rami Biram, Juan Delgado‐SanMartin, Alexander M. K. Rothman, Sofia S. Villar, Andreas A. Roussakis, Jurjan Aman, Ron A. A. Mathôt, Eleonora L. Swart, Martin R. Wilkins, Imke H. Bartelink   +13 more
wiley   +1 more source

Association between social vulnerability index and cataract surgery care in medicare beneficiaries: a retrospective cohort study. [PDF]

BMC Ophthalmol
Nguyen KC, Hall T, Gan S, Langnas E, Boscardin J, Sun CQ, Lee S, Chen CL.   +7 more
europepmc   +1 more source